Breaking News Instant updates and real-time market news.

NKTR

Nektar

$16.78

-0.4 (-2.33%)

16:14
10/23/19
10/23
16:14
10/23/19
16:14

Oppenheimer starts Nektar at Perform, calls shares fairy valued

Oppenheimer analyst Jay Olson initiated coverage of Nektar with a Perform rating and $18 price target. The shares are fairly valued at current levels, representing a "reasonable risk-reward balance" given Nektar's dependence on bempeg combination trials and potential upside from other drug candidates, Olson tells investors in a research note. The analyst thinks bempeg has a "below-average probability of success.:

NKTR Nektar
$16.78

-0.4 (-2.33%)

09/30/19
HCWC
09/30/19
NO CHANGE
Target $24
HCWC
Neutral
Competitive updates bring new challenges for Nektar bulls, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay sees "fresh challenges" for bulls of Nektar Therapeutics' bempeg following competitive updates this weekend in urothelial cancer and triple-negative breast cancer. The EV-103 study, which evaluated the combination of enfortumab vedotin plus pembrolizumab in previously untreated, locally advanced or metastatic urothelial cancer, who were ineligible for cisplatin-based chemotherapy, delivered an overall response rate of 71%, Chattopadhyay tells investors in a research note. This is well above the 48% ORR reported for the bempeg plus nivolumab combination in a potentially similar patient population, adds the analyst, who keeps a Neutral rating on Nektar shares with a $24 price target.
10/08/19
GSCO
10/08/19
DOWNGRADE
Target $16
GSCO
Sell
Nektar Therapeutics downgraded to Sell from Buy at Goldman Sachs
Goldman Sachs analyst Paul Choi double downgraded Nektar Therapeutics to Sell from Buy with a price target of $16, down from $54. The stock closed Monday down 30c to $18.67. Near-term catalysts are unlikely to re-rate the stock higher in the face of quality issues and a narrower focus for bempegaldesleukin, Choi tells investors in a research note. The shares over the past 18 months have underperformed as execution missteps related to suboptimal batches overshadowed original announcements of mostly positive clinical developments, says the analyst. Even with shares down over 60% since its January 19 high, the analyst thinks uncertainty on bempeg's safety or efficacy, as well as Nektar's ability to execute on a large-scale clinical development program, will likely continue to be an overhang on shares.
10/08/19
10/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Oracle (ORCL), Carbonite (CARB), and Check Point (CHKP) downgraded to Hold from Buy at Jefferies. 2. TerraForm Power (TERP) downgraded to Equal Weight from Overweight at Barclays. 3. Puma Biotechnology (PBYI) downgraded to Sell from Neutral at Goldman Sachs while Nektar Therapeutics (NKTR) was double downgraded to Sell from Buy. 4. Qiagen (QGEN) downgraded to Underweight from Neutral at JPMorgan and to Equal Weight from Overweight at Barclays. 5. Helmerich & Payne (HP) and Patterson-UTI (PTEN) downgraded to Neutral from Buy at BofA/Merrill. Nine Energy Services (NINE) and FTS International (FTSI) downgraded to Underperform from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/19
OPCO
10/23/19
INITIATION
Target $18
OPCO
Perform
Nektar initiated with a Perform at Oppenheimer
Oppenheimer analyst Jay Olson initiated coverage of Nektar with a Perform rating and $18 price target.

TODAY'S FREE FLY STORIES

DNA

Bought by RHHBY

$0.00

(0.00%)

14:23
11/18/19
11/18
14:23
11/18/19
14:23
Conference/Events
Wolfe Research pharma analyst to hold an analyst/industry webcast »

Global Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOR

MorphoSys

$28.22

2.08 (7.96%)

14:18
11/18/19
11/18
14:18
11/18/19
14:18
Recommendations
MorphoSys analyst commentary  »

MorphoSys B-MIND futility…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/18/19
11/18
14:17
11/18/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/18/19
11/18
14:16
11/18/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOR

MorphoSys

$28.22

2.08 (7.96%)

14:14
11/18/19
11/18
14:14
11/18/19
14:14
Hot Stocks
MorphoSys says tafasitamab B-MIND study successfully passed futility analysis »

Earlier, MorphoSys…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

DISCA

Discovery

$30.74

1.03 (3.47%)

14:03
11/18/19
11/18
14:03
11/18/19
14:03
Hot Stocks
Discovery rises after Malone buys $75M worth of stock »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$196.73

1.66 (0.85%)

14:01
11/18/19
11/18
14:01
11/18/19
14:01
Options
Call volume jumps in Facebook as shares and implied volatility lift »

Call volume jumps in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

ABMD

Abiomed

$190.75

-32.48 (-14.55%)

13:54
11/18/19
11/18
13:54
11/18/19
13:54
Hot Stocks
Abiomed falls after studies question Impella heart device at AHA 2019 meeting »

In a story out over the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNI

McClatchy

$0.56

0.0846 (17.63%)

13:53
11/18/19
11/18
13:53
11/18/19
13:53
Hot Stocks
Bluestone Financial raises stake in McClatchy to 11.85% »

Bluestone Financial holds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSII

Heidrick & Struggles

$29.39

-0.04 (-0.14%)

13:50
11/18/19
11/18
13:50
11/18/19
13:50
Initiation
Heidrick & Struggles initiated  »

Heidrick & Struggles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

13:50
11/18/19
11/18
13:50
11/18/19
13:50
General news
Fed's Mester said she would have preferred to have kept rates steady »

Fed's Mester said…

CL

Colgate-Palmolive

$67.08

0.71 (1.07%)

13:45
11/18/19
11/18
13:45
11/18/19
13:45
Options
Colgate Palmolive call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRTX

Karuna Therapeutics

$73.20

55.94 (324.10%)

13:43
11/18/19
11/18
13:43
11/18/19
13:43
Recommendations
Karuna Therapeutics analyst commentary  »

Karuna Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

STNE

StoneCo

$37.17

-0.73 (-1.93%)

13:35
11/18/19
11/18
13:35
11/18/19
13:35
Options
StoneCo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

13:35
11/18/19
11/18
13:35
11/18/19
13:35
General news
Treasury Action: yields remain modestly lower on the day »

Treasury Action: yields…

I

Intelsat

$11.26

-2.14 (-15.97%)

13:29
11/18/19
11/18
13:29
11/18/19
13:29
Hot Stocks
CBA responds to announcement by FCC Chair regarding C-band spectrum proceeding »

The C-Band Alliance, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ARWR

Arrowhead

$48.38

0.95 (2.00%)

13:27
11/18/19
11/18
13:27
11/18/19
13:27
Recommendations
Arrowhead analyst commentary  »

Arrowhead data validates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.27

-0.27 (-0.61%)

13:25
11/18/19
11/18
13:25
11/18/19
13:25
Hot Stocks
Altitude Sports files antitrust suit against Comcast »

Altitude Sports &…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.27

-0.27 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

EQT

EQT Corporation

$9.70

-0.64 (-6.19%)

13:25
11/18/19
11/18
13:25
11/18/19
13:25
Options
EQT Corporation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

AGIO

Agios Pharmaceuticals

$36.81

1.17 (3.28%)

, ETNB

89bio

$27.29

1.26 (4.84%)

13:25
11/18/19
11/18
13:25
11/18/19
13:25
On The Fly
Fly Insider: 89Bio, Addus Homecare among week's notable insider trades »

Welcome to "Fly Insider,"…

AGIO

Agios Pharmaceuticals

$36.81

1.17 (3.28%)

ETNB

89bio

$27.29

1.26 (4.84%)

GRTX

Galera Therapeutics

$12.06

0.11 (0.92%)

ARVN

Arvinas

$31.31

0.89 (2.93%)

TRN

Trinity Industries

$20.92

-0.295 (-1.39%)

ADUS

Addus HomeCare

$85.34

1.07 (1.27%)

AL

Air Lease

$44.90

-0.58 (-1.28%)

AMED

Amedisys

$155.36

2.65 (1.74%)

BLKB

Blackbaud

$83.98

0.23 (0.27%)

BOKF

BOK Financial

$81.03

-0.88 (-1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 13

    Dec

ZEN

Zendesk

$76.48

1.05 (1.39%)

13:22
11/18/19
11/18
13:22
11/18/19
13:22
Hot Stocks
Helpshift announces integration with Amazon Connect »

Helpshift announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 09

    Dec

  • 11

    Dec

MO

Altria Group

$48.47

0.5 (1.04%)

13:19
11/18/19
11/18
13:19
11/18/19
13:19
Hot Stocks
California sues Juul for lack of oversight on sales to minors »

California Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
11/18/19
11/18
13:17
11/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$11.33

-2.07 (-15.45%)

13:16
11/18/19
11/18
13:16
11/18/19
13:16
Hot Stocks
Eutelsat says 'looks forward to engaging' with FCC on C-band spectrum plans »

Eutelsat Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
11/18/19
11/18
13:16
11/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.